Boston Scientific (NYSE: BSX)

When you're hot, you're hot, and medical device maker Boston Scientific (NYSE: BSX) is sizzling. On Monday, the stock spiked 3.35% to a four-year high after receiving a double dose of upgrades from analysts at Morgan Stanley (NYSE: MS) and Oppenheimer (NYSE: OPY).

Shares continued to climb Tuesday, and the latest move in the stock is telling us that the bull run in BSX just doesn't want to stop -- and hey, why should it?

According to David Lewis, who follows the stock for Morgan Stanley, BSX deserves his bullish "overweight" rating in large part because of the strength in the company's pipeline and its opportunities for margin expansion.

"Over the past several years, the company has targeted investments across several markets to accelerate growth and drive leverage," wrote Lewis in a note to clients. "We believe better recognition of this strategy will drive future out performance even after a robust 2013 as accelerating sales and earnings growth drive improving financial performance over the next several years."  (more)

Please share this article